



## NEWS RELEASE

### DEFYRUS COMPLETES SECONDARY EQUITY FINANCING INCREASING TOTAL FUNDS RAISED TO \$4.2 MILLION

For Immediate Release

October 23<sup>rd</sup>, 2009

---

**Toronto** - Defyrus Inc. today announced the completion of a Series A secondary tranche of equity financing. The investment was made by Tancho Innovation Capital (<http://tanchocapital.com/>) and involved participation from individual investors in North America and Europe. Use of proceeds includes; GMP manufacturing of two lead drug candidates and advancing preclinical development to support clinical trial applications.

Dr. Jeffrey D. Turner, President & Chief Executive Officer of Defyrus, said: "Tancho was successful in raising the additional equity because of management's significant progress in the past twelve months. This financing, in addition to the initial Series A financing, provides management with the necessary capital to deliver our business plan to develop and manufacture drugs to counter bioterrorists threats and emerging infectious disease. In addition the company will continue to leverage this investment through public health and military collaborative initiatives."

#### **About Defyrus**

Defyrus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom and Canada to develop broad spectrum anti-viral drugs and vaccines as medical countermeasures to bioterrorist threats and emerging infectious diseases. [www.defyrus.com](http://www.defyrus.com)

###

#### **For further information:**

Dr. Jeffrey D. Turner  
President & CEO  
Tel: (613) 674-1138  
[info@defyrus.com](mailto:info@defyrus.com)

Mr. Dana Rath  
Chief Financial Officer  
Tel: (514) 231-3554  
[info@defyrus.com](mailto:info@defyrus.com)